Patents by Inventor Toyohiro Sawada
Toyohiro Sawada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8197846Abstract: The present invention provides a sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and, when a dissolution test is carried out according to Japanese Pharmacopoeia Dissolution Test Method 2, the tamsulosin release after 7 hours from the start of the dissolution is about 20 to about 85%.Type: GrantFiled: May 10, 2004Date of Patent: June 12, 2012Assignee: Astellas Pharma Inc.Inventors: Kazuhiro Sako, Toyohiro Sawada, Keiichi Yoshihara, Hiroyuki Kojima
-
Publication number: 20120088838Abstract: The present invention provides a sustained-release pharmaceutical composition, characterized in that there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.Type: ApplicationFiled: December 16, 2011Publication date: April 12, 2012Applicant: Astellas Pharma Inc.Inventors: Kazuhiro Sako, Toyohiro Sawada, Hiromu Kondo, Keiichi Yoshihara, Hiroyuki Kojima
-
Patent number: 8128958Abstract: The present invention provides a sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin/Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.Type: GrantFiled: May 10, 2004Date of Patent: March 6, 2012Assignee: Astellas Pharma Inc.Inventors: Kazuhiro Sako, Toyohiro Sawada, Hiromu Kondo, Keiichi Yoshihara, Hiroyuki Kojima
-
Patent number: 7871644Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption/by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.Type: GrantFiled: September 10, 2004Date of Patent: January 18, 2011Assignee: Astellas Pharma Inc.Inventors: Shunsuke Watanabe, Shigeo Takemura, Yuuki Tsutsui, Himoru Kondo, Kiyo Nakanishi, Kazuhiro Sako, Toyohiro Sawada
-
Publication number: 20090035372Abstract: The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is uniformly dispersed in the above-mentioned polyethylene oxide, a controlled-release pharmaceutical composition containing this sized product, and a method of manufacturing a controlled-release pharmaceutical composition containing this sized product. A controlled-release pharmaceutical composition with good uniformity of content can be presented by using powder particles of polyethylene oxide with powder properties suitable for tableting, which is obtained by uniform dispersion of the specific size controlling agent for polyethylene oxide of the present invention.Type: ApplicationFiled: October 2, 2008Publication date: February 5, 2009Applicant: Astellas Pharma Inc.Inventors: Akio Sugihara, Kazuhiro Sako, Toyohiro Sawada
-
Patent number: 7442387Abstract: The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is uniformly dispersed in the above-mentioned polyethylene oxide, a controlled-release pharmaceutical composition containing this sized product, and a method of manufacturing a controlled-release pharmaceutical composition containing this sized product. A controlled-release pharmaceutical composition with good uniformity of content can be presented by using powder particles of polyethtylene oxide with powder properties suitable for tableting, which is obtained by uniform dispersion of the specific size controlling agent for polyethylene oxide of the present invention.Type: GrantFiled: December 23, 2003Date of Patent: October 28, 2008Assignee: Astellas Pharma Inc.Inventors: Akio Sugihara, Kazuhiro Sako, Toyohiro Sawada
-
Publication number: 20080199522Abstract: The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement, a timed-release compression-coated solid composition for oral administration, said composition comprising (1) drug and freely erodible filler are mixed with the core tablet, (2) the percentage erosion of the core tablet is approximately 40 to approximately 90%, and (3) the outer layer essentially does not contain the same drug as the above-mentioned drug. By releasing a drug after a specific lag time, it becomes possible to effectively deliver a drug to a specific site in the digestive tract.Type: ApplicationFiled: August 20, 2007Publication date: August 21, 2008Applicant: Astellas Pharma, Inc.Inventors: Toyohiro Sawada, Kazuhiro Sako, Tatsunobu Yoshioka, Shunsuke Watanabe
-
Publication number: 20060292221Abstract: The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement, a timed-release compression-coated solid composition for oral administration, said composition comprising (1) drug and freely erodible filler are mixed with the core tablet, (2) the percentage erosion of the core tablet is approximately 40 to approximately 90%, and (3) the outer layer essentially does not contain the same drug as the above-mentioned drug. By releasing a drug after a specific lag time, it becomes possible to effectively deliver a drug to a specific site in the digestive tract.Type: ApplicationFiled: August 9, 2006Publication date: December 28, 2006Applicant: Astellas Pharma, Inc.Inventors: Toyohiro Sawada, Kazuhiro Sako, Tatsunobu Yoshioka, Shunsuke Watanabe
-
Patent number: 7008640Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.Type: GrantFiled: July 16, 2001Date of Patent: March 7, 2006Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Shunsuke Watanabe, Shigeo Takemura, Yuuki Tsutsui, Hiromu Kondo, Kiyo Nakanishi, Kazuhiro Sako, Toyohiro Sawada
-
Publication number: 20050163840Abstract: The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.Type: ApplicationFiled: June 10, 2004Publication date: July 28, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Toyohiro Sawada, Kazuhiro Sako, Tatsunobu Yoshioka, Shunsuke Watanabe
-
Publication number: 20050112206Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption/by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.Type: ApplicationFiled: September 10, 2004Publication date: May 26, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Shunsuke Watanabe, Shigeo Takemura, Yuuki Tsutsui, Himoru Kondo, Kiyo Nakanishi, Kazuhiro Sako, Toyohiro Sawada
-
Publication number: 20050100603Abstract: [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an ?1 receptor blocking action are reduced.Type: ApplicationFiled: May 10, 2004Publication date: May 12, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Kazuhiro Sako, Toyohiro Sawada, Hiromu Kondo, Keiichi Yoshihara, Hiroyuki Kojima
-
Publication number: 20050100602Abstract: [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting, there is a problem to provide a sustained-release pharmaceutical composition in which efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited. [Means for Resolution] A sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and, when dissolution test is carried out according to Japanese Pharmacopoeia Dissolution Test Method 2, the tamsulosin release after 7 hours from the start of the dissolution is about 20 to about 85%.Type: ApplicationFiled: May 10, 2004Publication date: May 12, 2005Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Kazuhiro Sako, Toyohiro Sawada, Keiichi Yoshihara, Hiroyuki Kojima
-
Publication number: 20040213845Abstract: The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is uniformly dispersed in the above-mentioned polyethylene oxide, a controlled-release pharmaceutical composition containing this sized product, and a method of manufacturing a controlled-release pharmaceutical composition containing this sized product.Type: ApplicationFiled: December 23, 2003Publication date: October 28, 2004Applicant: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Akio Sugihara, Kazuhiro Sako, Toyohiro Sawada
-
Patent number: 6761895Abstract: The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.Type: GrantFiled: April 12, 2001Date of Patent: July 13, 2004Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Toyohiro Sawada, Kazuhiro Sako, Tatsunobu Yoshioka, Shunsuke Watanabe
-
Patent number: 6699503Abstract: The invention provides a hydrogen-type sustained-release preparation comprising (1) at least one drug, (2) an additive which insures a penetration of water into the core of the preparation and (3) a hydrogen-forming polymer, wherein said preparation is capable of undergoing substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine and is capable of releasing the drug in the lower digestive tract including colon. By the preparation of the invention, the drug is efficiently released and absorbed even in the colon so that a steady and sustained release effect can be achieved.Type: GrantFiled: November 1, 2000Date of Patent: March 2, 2004Assignee: Yamanuchi Pharmaceutical Co., Ltd.Inventors: Kazuhiro Sako, Hiroshi Nakashima, Toyohiro Sawada, Akira Okada, Muneo Fukui
-
Publication number: 20030203024Abstract: The invention provides a hydrogel-type sustained-release preparation comprising (1) at least one drug, (2) an additive which insures a penetration of water into the core of the preparation and (3) a hydrogel-forming polymer, wherein said preparation is capable of undergoing substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine and is capable of releasing the drug in the lower digestive tract including colon.Type: ApplicationFiled: December 20, 2002Publication date: October 30, 2003Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.Inventors: Kazuhiro Sako, Hiroshi Nakashima, Toyohiro Sawada, Akira Okada, Muneo Fukui
-
Patent number: 6562375Abstract: The present invention is to provide a stable pharmaceutical composition for oral use and preparation thereof in which changes are prevented in drug release at stored even under the exposure to light by adding yellow ferric oxide and/or red ferric oxide in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The present invention is to further provide a method for preventing changes in drug release at stored under the exposure to light in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The quality assurance period of the product can be prolonged and the product value can be improved by the present invention.Type: GrantFiled: August 1, 2000Date of Patent: May 13, 2003Assignee: Yamanouchi Pharmaceuticals, Co., Ltd.Inventors: Kazuhiro Sako, Toyohiro Sawada, Keiichi Yoshihara, Tatsunobu Yoshioka, Shunsuke Watanabe
-
Publication number: 20020150624Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.Type: ApplicationFiled: July 16, 2001Publication date: October 17, 2002Inventors: Shunsuke Watanabe, Shigeo Takemura, Yuuki Tsutsui, Hiromu Kondo, Kiyo Nakanishi, Kazuhiro Sako, Toyohiro Sawada
-
Patent number: 6436441Abstract: The invention provides a hydrogel-type sustained-release preparation comprising (1) at least one drug, (2) an additive which insures a penetration of water into the core of the preparation and (3) a hydrogel-forming polymer, wherein said preparation is capable of undergoing substantially complete gelation during its stay in the upper digestive tract such as stomach and small intestine and is capable of releasing the drug in the lower digestive tract including colon. By the preparation of the invention, the drug is efficiently released and absorbed even in the colon so that a steady and sustained release effect can be achieved.Type: GrantFiled: March 20, 1995Date of Patent: August 20, 2002Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Kazuhiro Sako, Hiroshi Nakashima, Toyohiro Sawada, Akira Okada, Muneo Fukui